CA3067512A1 - Cannabidiolic acid esters compositions and uses thereof - Google Patents

Cannabidiolic acid esters compositions and uses thereof Download PDF

Info

Publication number
CA3067512A1
CA3067512A1 CA3067512A CA3067512A CA3067512A1 CA 3067512 A1 CA3067512 A1 CA 3067512A1 CA 3067512 A CA3067512 A CA 3067512A CA 3067512 A CA3067512 A CA 3067512A CA 3067512 A1 CA3067512 A1 CA 3067512A1
Authority
CA
Canada
Prior art keywords
branched
straight
compound according
disease
cbda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067512A
Other languages
English (en)
French (fr)
Inventor
Raphael Mechoulam
Linda Parker
Roger Pertwee
Aron WELLER
Joseph Tam
Christeen Haj
Reem Smoum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
University of Guelph
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Bar Ilan University filed Critical University of Guelph
Publication of CA3067512A1 publication Critical patent/CA3067512A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3067512A 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof Pending CA3067512A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3067512A1 true CA3067512A1 (en) 2018-12-27

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067512A Pending CA3067512A1 (en) 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof

Country Status (12)

Country Link
US (1) US11440870B2 (https=)
EP (1) EP3509638B1 (https=)
JP (1) JP2020524679A (https=)
CN (2) CN121534035A (https=)
AU (1) AU2018287018B2 (https=)
BR (1) BR112019026916A2 (https=)
CA (1) CA3067512A1 (https=)
DK (1) DK3509638T3 (https=)
ES (1) ES2909350T3 (https=)
MX (1) MX389847B (https=)
PT (1) PT3509638T (https=)
WO (1) WO2018235079A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
KR20210151816A (ko) * 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
JP2022545491A (ja) 2019-08-22 2022-10-27 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) * 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
WO1999057107A2 (en) 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US20050287180A1 (en) 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
CN102766128A (zh) 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
EP2842933B1 (de) * 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
EP3131874B1 (en) * 2014-04-16 2018-07-25 Emerald Health Pharmaceuticals Inc. Novel cannabidiol quinone derivatives
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
US11440870B2 (en) 2022-09-13
JP2020524679A (ja) 2020-08-20
AU2018287018B2 (en) 2022-04-28
US20200115317A1 (en) 2020-04-16
CN121534035A (zh) 2026-02-17
MX2019015311A (es) 2022-02-02
CN111032088A (zh) 2020-04-17
BR112019026916A2 (pt) 2020-06-30
DK3509638T3 (da) 2022-04-11
AU2018287018A1 (en) 2020-01-30
WO2018235079A1 (en) 2018-12-27
EP3509638A1 (en) 2019-07-17
EP3509638B1 (en) 2022-01-12
PT3509638T (pt) 2022-03-02
ES2909350T3 (es) 2022-05-06
MX389847B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
AU2018287018B2 (en) Cannabidiolic acid esters compositions and uses thereof
Pertwee et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats
EP2986289B1 (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
CN107405327B (zh) 大麻素化合物的混合物、其制备和应用
CN105517989B (zh) 大麻素类化合物的混合物及其制备和用途
ES2972711T3 (es) Tratamiento de enfermedades del CNS con estimuladores de la GCs
EP4255403A1 (en) Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
US20230218567A1 (en) Compound and method for treating diseases and disorders
CN102274227B (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
TW201805283A (zh) sGC刺激劑之固體形式
US8492431B2 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
MXPA06012564A (es) Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
CN101379063A (zh) 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
CN108218814A (zh) 靶向sirt3激动剂及其在aml治疗药物中的应用
JP2024527932A (ja) カンナビノイドのホスフェートプロドラッグ
KR20120081120A (ko) 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물
CN107446010A (zh) 一种红霉素衍生物及其制备方法和应用
CN102228696B (zh) 聚乙二醇-聚乙烯醇共聚物-美他沙酮前药及其合成方法
CN1318414C (zh) 含邻萘醌结构的化合物及其应用
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用
CN1690073A (zh) 甾体类衍生物
EP1940831A1 (en) Salicylate and gentisate salts of a piperazine compound
CN1736381B (zh) 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途